• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> METHOD FOR PREDICTING FIVE-YEAR NONMETASTATIC SURVIVAL IN BREAST CANCER PATIENTS BASED ON THE EXPRESSION OF THE YKL-39 AND CCL18 PROTEIN GENES

METHOD FOR PREDICTING FIVE-YEAR NONMETASTATIC SURVIVAL IN BREAST CANCER PATIENTS BASED ON THE EXPRESSION OF THE YKL-39 AND CCL18 PROTEIN GENES

机译：基于YKL-39和CCL18蛋白基因表达的乳腺癌患者五年非转移生存预测方法

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to oncology, and is designed to predict five-year non-metastatic survival in patients with breast cancer. Molecular genetic study of biopsy specimens of tumor tissue is carried out, followed by isolation of RNA and determination of the level of expression of YKL-39 and CCL18 genes with the help of a quantitative polymerase chain reaction in real time. As a calibrator, normal breast tissue is used, in which the expression level of the YKL-39 and CCL18 genes is 1UU. With expression level of YKL-39 and CCL18 greater than 1UU with a combination of YKL-39+CCL18+ genes predict 100 % five-year non-metastatic survival. In case of combinations YKL-39+CCL18−, YKL-39−CCL18+, YKL-39−CCL18− predict a risk of hematogenous metastases in 85 %, 71 % and 69 % of cases, respectively.;EFFECT: invention provides expansion of the field of application of the method by using an additional marker.;1 cl, 1 dwg, 4 ex
机译：发明领域本发明涉及医学，即肿瘤学，并且被设计用于预测乳腺癌患者的五年非转移存活。进行了肿瘤组织活检标本的分子遗传学研究，然后通过实时定量聚合酶链反应，分离RNA并确定YKL-39和CCL18基因的表达水平。作为校准物，使用正常的乳腺组织，其中YKL-39和CCL18基因的表达水平为1UU。当YKL-39和CCL18的表达水平大于1UU并结合YKL-39 + CCL18 + 基因时，可预测100％的五年非转移生存期。如果是YKL-39 + CCL18 -组合，则YKL-39 - CCL18 + ，YKL-39 < Sup>- CCL18 -分别预测85％，71％和69％的病例发生血源性转移的风险;效果：本发明扩大了该方法的应用范围通过使用其他标记。; 1 cl，1 dwg，4 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号